Abstract:Objective To evaluate the relevance of molecular alterations and histopathological subtypes of lung adenocarcinoma according to 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. Methods Mutations of epidermal growth factor receptor (EGFR) 18-21 exons ( E18-21 ),KRAS 12/13 codons and EML4-ALK fusion in 212 cases of lung adenocarcinoma which underwent complete tumor resection,were detected by immunohistochemistry,PCR-amplifying and gene sequencing.The relevance of the molecular alterations to histopathological subtypes based on the new classification and 2004 WHO classification were further characterized. Results Mutations of EGFR were observed in 49.6％ of lung adenocarcinomas,involving mainly E21 (52.4％,55/105 ) and E19 ( 36.2％,38/105). Mutations of KRAS were detected in 8％ cases of adenocarcinoma,involving mainly codon 12 (15/17). EML4-ALK fusions were found in 6.1％ of lung adenocarcinoma,the most common fusion mutation was type V1 ( E13; A20) (7/13),followed by type V3a/b ( E6a/b; A20) (4/13).Based on the new classification, 7/10 lepidic, 63.2％ (48/76) papillary, and 5/8 micropapillary predominant adenocarcinomas harbored EGFR mutations. EGFR mutations showed significant difference among different histological subtypes (P =0.008). KRAS mutations were most frequently found in invasive mucinous adenocarcinoma (1/2),followed by colloid predominant adenocarcinoma (3/7). There was siguificant difference of KRAS mutations among different histological subtypes ( P =0.003 ).EMLA-ALK fusions were most frequently found in the solid predominant with mucin production subtype ( 15.4％,6/39),followed by colloid predominant adenocarcinoma ( 1/7 ),and no significant difference of EMLA-ALK fusions was found among different histological subtypes ( P =0.181 ). Significant TTF-1 overexpression was observed in adenocarcinomas harbored EGFR mutations (P =0.008 ),and no or significantly lower level expression of TTF-1 was observed in adenocarcinomas harbored KRAS mutations (P =0.000). However,there was no association between TTF-1 expression and EML4-ALK fusions ( P =0.274 ). Based on the 2004 WHO classification,mutations of KRAS ( P =0.002 ) and EML4-ALK (P =0.000),rather than EGFR ( P =0.502),showed significant differences among different subtypes. According to both classification systems,the difference of " triple negative" adenocarcinomas was not significant among different subtypes ( P =0.684,P =0.449, respectively ). Conclusions The new classification, combined with TTF-1 immunomarker,can help to predict the molecular alterations of EGFR and KRAS genes,but can not indicate the EML4-ALK fusion in lung adenocarcinoma. Lepidic, papillary, and micropapillary predominant adenocarcinomas with TTF-1 expression are closely related to the presence of EGFR mutation,and invasive mucinous adenocarcinoma,while colloid predominant adenocarcinoma without TTF-1 expression is closely related to the presence of KRAS mutation.

Changes of 2015 WHO Histological Classiifcation of Lung Cancer and the Clinical Signiifcance

2011 New Lung Adenocarcinoma Multidisciplinary Classification:imaging aspects

Interpretation of Pleura, Pericardium and Thymus Tumours Updates in the WHO Classification of Thoracic Tumours (5th Edition)

Prognostic Significance of the IASLC/ATS/ERS Classification in Chinese Patients—a Single Institution Retrospective Study of 292 Lung Adenocarcinoma

High-resolution gas chromatography/mass spectrometric analysis of tobacco and marijuana sterols

Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

[New WHO Classification of Lymphoid Neoplasms: Understanding and Consideration].

[Large-Cell Lung Carcinoma by the 2015 WHO Classification: a Clinicopathologic Analysis of 93 Cases].

The Earliest Stage of Lung Adenocarcinoma: the Pathological Diagnosis and Clinical Significance of Adenocarcinoma in Situ

The Morphological Changes of Bronchovascular Bundles Within Subsolid Nodules on HRCT Correlate with the New IASLC Classification of Adenocarcinoma.

Molecular Markers in the World Health Organization Classification of Head and Neck Tumors, Fifth Edition

New WHO Classification Changing the Strategy of Clinical Treatment--A Recognition of Inflammatory Myofibroblastic Tumor

Clinicopathological Analysis of Large Cell Lung Carcinomas Definitely Diagnosed According to the New World Health Organization Criteria.

Interpretation and reunderstanding of the updated pathological classification of renal tumors of World Health Organization in 2022

The Grading System for Lung Adenocarcinoma: Brief Review of its Prognostic Performance and Future Directions

Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival

The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds

The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.

Characteristics and Prognostic Analysis of 193 Patients with Special Type of Lung Adenocarcinoma

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer